Back to Authors

Pace, Amy

https://orcid.org/0000-0003-4217-1345

A5102941773 | I4210125492

Mayo Clinic

Alexion Pharmaceuticals (United States)

Citations 3

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1788

Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1299

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

New England Journal of Medicine | May 3, 2019 | Volume: 381 | Issue: 7 | Pages: 614-625

10.1056/nejmoa1900866 | PMID 31050279